Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia



Status:Recruiting
Conditions:Healthy Studies, Schizophrenia, Psychiatric, Psychiatric
Therapuetic Areas:Psychiatry / Psychology, Other
Healthy:No
Age Range:18 - 50
Updated:3/6/2019
Start Date:April 1, 2018
End Date:March 2021
Contact:Jo Talledo Benrubi, B.A.
Email:atalledo@ucsd.edu
Phone:6195433093

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
This application seeks to determine if neurophysiological metrics of memantine (MEM)-enhanced
early auditory information processing (EAIP) in schizophrenia (SZ) mediate gains in auditory
processing fidelity (APF) and auditory learning.


Inclusion Criteria:

- diagnosis of schizophrenia OR schizoaffective-depressed OR healthy subjects

- ages 18-50 for all subjects

- double barrier contraception for all subjects

- not pregnant for all subjects

Exclusion Criteria:

- DSM-IV Axis I or II Diagnosis for for healthy subjects

- MEM or amantadine for patients

- current substance abuse for all subjects

- current recreational drug use for all subjects

- history of other significant medical illness (e.g. cancer, diabetes, heart disease,
HIV, seizures) for all subjects

- open head injury or closed head injury with loss of consciousness > 1 min for all
subjects

- hearing or visual impairment for all subjects

- pregnancy for all subjects

- dementia for all subjects

- mental retardation for all subjects
We found this trial at
1
site
Clinical Teaching Facility (CTF-B102) at UCSD Medical Center
San Diego, California 92103
Principal Investigator: Neal R. Swerdlow, M.D., Ph.D.
Phone: 619-543-3093
?
mi
from
San Diego, CA
Click here to add this to my saved trials